Tissue Repair (ASX:TRP) receives second US patent for Glucoprime

• Tissue Repair (TRP) receives a second US patent for its topical skin treatment active ingredient, Glucoprime
• Glucoprime is an active pharmaceutical ingredient (API) used to treat skin conditions like burns, pressure ulcers and post-procedure wounds whether it be surgical or cosmetic
• This latest patent grants Tissue Repair with exclusive rights to use Glucoprime as a topical application to treat a large number of skin conditions
• It follows TRP’s first patent approval in April 2022 which granted the company exclusive rights to the method of manufacturing
• TRP shares are up 6.45 per cent to close at 33 cents

Tissue Repair (TRP) has been granted a second US patent for its topical skin treatment active ingredient, Glucoprime.

Glucoprime is an active pharmaceutical ingredient (API) used to treat skin conditions like burns, pressure ulcers or any post-procedure wounds whether it be surgical or cosmetic.

Glucoprime is also the API used in the company’s first drug candidate, TR-987, which treats leg ulcers, as well as TR Pro+, which is used as a post-operative cosmeceutical application.

Tissue Repair is currently one of a number of advanced biotechnology companies around the world that is seeking to enter a phase three program in venous leg ulcers.

The company says if trials of TR-987 are successful, it would be the first drug approved for venous leg ulcers in over 25 years.

The granting of this patent means Tissue Repair has exclusive rights to use Glucoprime as a topical application to treat a large number of skin conditions in very large markets.

It follows the company’s first patent approval in April 2022 which claimed the method of manufacturing of Glucoprime.

To date, there are no other known methods to produce the proprietary biological polysaccharide molecule.

“The patent is significant as it provides broad protection for the use of our proprietary Glucoprime technology across its current dual focus of Chronic wounds and post-procedure cosmetic healing, as well as extending protection into any topically applied skin condition, such as pressure ulcers, diabetic foot ulcers, surgical wounds and burns,” Co-Founder Tony Charara said.

TRP shares were up 6.45 per cent to close at 33 cents.